Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...

Educational P-Code Virtual Machine and Debugger plugin for IntelliJ IDEA. P-Code VM helps students learn compiler construction, intermediate code generation, stack machines, recursion, frames, and ...

Thanks for attending the 2026 Bank of America Healthcare Conference. My name is Alec Stranahan. I cover Recursion and SMid Biotech at Bank of America. And I'm pleased to be joined today by Ben Taylor, ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Abstract: Return-Oriented Programming (ROP) attacks pose a significant threat to the control-flow integrity of Internet of Things (IoT) devices, which operate in resource-constrained environments with ...

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...